Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03231800
Recruitment Status : Completed
First Posted : July 27, 2017
Results First Posted : June 24, 2020
Last Update Posted : June 24, 2020
Sponsor:
Information provided by (Responsible Party):
Sunovion

Tracking Information
First Submitted Date  ICMJE July 24, 2017
First Posted Date  ICMJE July 27, 2017
Results First Submitted Date  ICMJE June 4, 2020
Results First Posted Date  ICMJE June 24, 2020
Last Update Posted Date June 24, 2020
Actual Study Start Date  ICMJE July 31, 2017
Actual Primary Completion Date March 15, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 4, 2020)
Change From Baseline at Day 15 in , ADHD Symptoms as Measured by Mean Swanson,Kotkin,Agler,M-Flynn, Pelham Rating Scale(SKAMP)-Combined Score Obtained From an Average of the 7 Assessments Collected Across the 12-hour Classroom Day(12 to 24 Hours Postdose) [ Time Frame: Baseline to Day 15 ]
The Swanson, Kotkin, Agler, M-Flynn, Pelham Rating Scale (SKAMP) scale is a 13-item independent observer rating of subject impairment of classroom observed behaviors. Each item is rated on a 7-point impairment scale (0 = normal to 6 = maximal impairment). The combined scores for the SKAMP are obtained by summing the values of all 13 items in the assessment. The range of SKAMP combined score is 0-78, with higher values represent a worse outcome.
Original Primary Outcome Measures  ICMJE
 (submitted: July 24, 2017)
change from baseline at Day 15 in ADHD symptoms as measured by mean SKAMP-Combined score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose). [ Time Frame: Baseline to Day 15 ]
The primary endpoint is change from baseline at Day 15 in ADHD symptoms as measured by mean SKAMP-Combined score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose). Time Frame: Baseline to Day 15 The primary endpoint is change from baseline at Day 15 in ADHD symptoms as measured by mean SKAMP-Combined score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose). Time Frame: Baseline to Day 15 The primary endpoint is change from baseline at Day 15 in ADHD symptoms as measured by mean SKAMP-Combined score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 4, 2020)
  • Change From Baseline at Day 15 in Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)Attention Subscale Score Obtained From the 7 Assessments Collected Across the 12-hour Classroom Day (12 to 24 Hours Postdose) [ Time Frame: Baseline to Day 15 ]
    The Swanson, Kotkin, Agler, M-Flynn, Pelham Rating Scale (SKAMP) scale is a 13-item independent observer rating of subject impairment of classroom observed behaviors. Each item is rated on a 7-point impairment scale (0 = normal to 6 = maximal impairment). The Attention Subscale scores for the SKAMP are obtained by summing the values of Items 1-4 in the assessment. The range of SKAMP Attention Subscale score is 0-24, with higher values represent a worse outcome.
  • Change From Baseline at Day 15 in Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Deportment Subscale Score Obtained From the 7 Assessments Collected Across the 12-hour Classroom Day (12 to 24 Hours Postdose) [ Time Frame: Baseline to Day 15 ]
    The Swanson, Kotkin, Agler, M-Flynn, Pelham Rating Scale (SKAMP) scale is a 13-item independent observer rating of subject impairment of classroom observed behaviors. Each item is rated on a 7-point impairment scale (0 = normal to 6 = maximal impairment). The Deportment Subscale scores for the SKAMP are obtained by summing the values of Items 5-8 in the assessment. The range of SKAMP Deportment Subscale score is 0-24, with higher values represent a worse outcome.
  • Change From Baseline at Day 15 in Mean Permanent Product Measure of Performance (PERMP)-Attempted Problems Scores Obtained From the 7 Assessments Collected Over the 12-hour Classroom Day (12-24-hours Postdose) [ Time Frame: Baseline to Day 15 ]
    The Permanent Product Measure of Performance (PERMP) is a math test consisting of 400 problems. Both attempted problems and correct problems are assessed. Subjects are to complete as many problems as possible in 10 minutes. Performance is measured by the number of math problems attempted and the number of math problems correctly completed. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.
  • Change From Baseline at Day 15 in Mean Permanent Product Measure of Performance (PERMP)-Correct Problems Scores Obtained From the 7 Assessments Collected Over the 12-hour Classroom Day (12-24-hours Postdose) [ Time Frame: Baseline to Day 15 ]
    The Permanent Product Measure of Performance (PERMP) is a math test consisting of 400 problems. Both attempted problems and correct problems are assessed. Subjects are to complete as many problems as possible in 10 minutes. Performance is measured by the number of math problems attempted and the number of math problems correctly completed. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 24, 2017)
  • Mean SKAMP-Combined score from the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose) on Day 15 [ Time Frame: Day 15 ]
    Mean SKAMP-Combined score from the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose) on Day 15
  • SKAMP-Combined score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15 [ Time Frame: Day 15 ]
    SKAMP-Combined score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15
  • Change from baseline at Day 15 in SKAMP-Combined score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in SKAMP-Combined score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day
  • Change from baseline at Day 15 in mean SKAMP-Attention subscale score obtained from the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose) [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in SKAMP-Combined score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day
  • SKAMP-Attention subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15 [ Time Frame: Day 15 ]
    SKAMP-Attention subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15
  • Change from baseline at Day 15 in SKAMP-Attention subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in SKAMP-Attention subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day
  • Change from baseline at Day 15 in mean SKAMP-Deportment subscale score obtained from the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose) [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in mean SKAMP-Deportment subscale score obtained from the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose)
  • SKAMP-Deportment subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15 Time Frame: Day 15 [ Time Frame: Day 15 ]
    SKAMP-Deportment subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15 Time Frame: Day 15
  • Change from baseline at Day 15 in SKAMP-Deportment subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in SKAMP-Deportment subscale score at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day
  • Change from baseline at Day 15 in Permanent Product Measure of Performance (PERMP)-Attempted and Correct Problems scores at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in Permanent Product Measure of Performance (PERMP)-Attempted and Correct Problems scores at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day
  • PERMP-Attempted and Correct Problems scores at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15 [ Time Frame: Day 15 ]
    PERMP-Attempted and Correct Problems scores at each of the assessment times (12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day 15
  • Change from baseline at Day 15 in mean PERMP-Attempted score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose). [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in mean PERMP-Attempted score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose).
  • Change from baseline at Day 15 in mean PERMP-Correct score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose). [ Time Frame: Baseline to Day 15 ]
    Change from baseline at Day 15 in mean PERMP-Correct score obtained from an average of the 7 assessments collected across the 12-hour classroom day (12 to 24 hours postdose).
  • The incidence of overall AEs, serious AEs (SAEs), and AEs (or SAEs) leading to discontinuations [ Time Frame: Day 15 ]
    The incidence of overall AEs, serious AEs (SAEs), and AEs (or SAEs) leading to discontinuations
  • Absolute values and change from baseline in clinical laboratory evaluations (serum chemistry, hematology, and urinalysis) [ Time Frame: Day 15 ]
    Absolute values and change from baseline in clinical laboratory evaluations (serum chemistry, hematology, and urinalysis)
  • Absolute values and changes from baseline in vital signs, body weights, and 12-lead ECGs [ Time Frame: Baseline to Day 15 ]
    Absolute values and changes from baseline in vital signs, body weights, and 12-lead ECGs
  • Frequency of and severity of suicidal ideation and suicidal behavior as assessed by the C-SSRS [ Time Frame: Baseline to Day 15 ]
    Frequency of suicidal ideation and suicidal behavior as assessed by the C-SSRS
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Official Title  ICMJE Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Brief Summary A study to evaluate the efficacy and safety of dasotraline in children 6 to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
Detailed Description

This is a randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study in children with ADHD in a laboratory classroom setting. The study will be comprised of 3 periods: Screening (up to 35 days) including a 3 - 5 day ADHD medication washout prior to Day -1; Double-blind randomized treatment with either dasotraline (2 mg/day) or placebo for 14 days; and a final safety evaluation 7 days after last dose. Prior to the start of treatment (Day 1) and following the conclusion of the double-blind period (Day 15), subjects will undergo a full-day laboratory classroom evaluation in cohorts of up to 18 subjects. Each laboratory classroom day will include seven 30-minute simulated classroom sessions where trained observers will assess subjects using the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Scale. In addition during each classroom session, a 10-minute math test (Permanent Product Measure of Performance [PERMP]) will be administered to evaluate sustained attention and effort. Seven (± 2) days after the last dose of study drug, subjects will return to the clinic and complete safety assessments.

This study is designed to test the superiority of dasotraline 2 mg/day against placebo based on Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP)-Combined score in pediatric subjects aged 6-12 years with ADHD who weigh ≤ 30 kg

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This is a randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study in children with ADHD in a laboratory classroom setting
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double Blind
Primary Purpose: Treatment
Condition  ICMJE Attention-Deficit Hyperactivity Disorder (ADHD)
Intervention  ICMJE
  • Drug: dasotraline
    dasotraline 2mg capsule once daily
    Other Name: SEP-225289
  • Drug: Placebo
    Placebo capsule once daily
Study Arms  ICMJE
  • Experimental: Dasotraline
    Dasotraline capsule 2mg/day
    Intervention: Drug: dasotraline
  • Placebo Comparator: Placebo
    Placebo capsule
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 1, 2019)
95
Original Estimated Enrollment  ICMJE
 (submitted: July 24, 2017)
100
Actual Study Completion Date  ICMJE March 15, 2019
Actual Primary Completion Date March 15, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subject is 6 - 12 years old, inclusive at screening and randomization.
  2. Subject weighs ≤ 30 kg at the time of screening.
  3. At least one of the subject's parents/legal guardians must give written informed consent, including privacy authorization, prior to study participation. The subject will provide informed assent prior to study participation.
  4. Subject meets Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria for a primary diagnosis of ADHD (inattentive, hyperactive, or combined presentation) at screening established by a comprehensive psychiatric evaluation that reviews DSM-5 criteria and confirmed using the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL) at screening.
  5. Subject is currently either untreated for ADHD or receiving a treatment regimen of a stimulant medication prescribed as monotherapy (i.e., methylphenidate, mixed amphetamine salts, lisdexamphetamine, or dextroamphetamine) within the approved labeled dose range for ADHD..
  6. In the opinion of the investigator, the subject is not treatment refractory.
  7. Any subject not receiving ADHD medication at screening must display clinically significant ADHD symptoms, as measured by an ADHD-RS-IV score ≥ 26 at screening and Day -7.
  8. For any subject receiving monotherapy stimulant treatment for ADHD, that treatment must be well tolerated and clinically effective based on clinical assessment and informant interview, as well as, review of available medical records. Note: The ADHD Rating Scale Version IV - Home Version (modified for investigator administration) (ADHD RS IV HV) will be administered at Screening by the investigator to inform clinical evaluation.
  9. Subject is male or a non-pregnant, non-lactating female.
  10. Subject, if female, must not be pregnant or breastfeeding, and if ≥ 8 years of age must have a negative serum pregnancy test at screening.
  11. Female subjects of childbearing potential and male subjects with female partners of childbearing potential must practice true abstinence (consistent with lifestyle) and must agree to remain abstinent or agree to use an effective and medically acceptable form of birth control, from the time of informed consent/assent to at least 14 days after the last dose of the study drug has been taken.
  12. Subject must be in general good health (defined as the absence of any clinically relevant abnormalities as determined by the investigator) based on screening physical and neurological examinations, medical history, and clinical laboratory values (hematology, chemistry, and urinalysis). Note: If any of the hematology, chemistry, or urinalysis results are not within the laboratory's reference range, then the subject can be included only if the investigator determines the deviations to be not clinically relevant.
  13. Subject is within the 3rd to 97th percentile for gender specific weight-for-age from the Centers for Disease Control and Prevention (CDC) growth charts
  14. Subject must report a history of being able to swallow capsules.
  15. Subject and subject's parent/legal guardian must be able to fully comprehend the informed consent/assent forms, understand and be willing and able to comply with all study procedures and visit schedule, and be able to communicate satisfactorily with the investigator and study coordinator.
  16. Subject, on Day -1, has evidence of clinically significant ADHD symptoms as measured by an ADHD RS IV HV total score ≥ 26. If subject has been receiving stimulant pharmacotherapy for ADHD the ADHD RS-IV should be administered following a minimum 72 hour washout from prior ADHD medication treatment.

Exclusion Criteria:

  1. Subject or parent/legal guardian has commitments during the study that would interfere with attending study visits.
  2. Subject is currently being treated for ADHD with a non-stimulant product, or has been treated with a non-stimulant product in the 4 weeks prior to the start of screening.
  3. Subject has failed 2 adequate courses (dose and duration) of stimulant or non-stimulant treatment for ADHD.
  4. Subject is considered treatment refractory, as judged by the investigator.
  5. Subject currently has a diagnosis of asthma that has required daily treatment with bronchodilators or nebulizer treatments in the 30 days prior to screening and/or who may require daily treatments with these agents over the course of the trial. Intermittent use of bronchodilators is not exclusionary. Subjects who have a history of requiring persistent asthma treatment should be discussed with the medical monitor prior to randomization.
  6. Subject has any clinically significant unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of a condition (eg, malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion. Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the medical monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the medical monitor during screening.
  7. Subject has a history or presence of abnormal ECGs, which in the investigator's opinion is clinically significant. Screening site ECGs will be centrally over-read, and eligibility will be determined by the investigator based on the results of the over-read report.
  8. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances. Note: Subjects with oppositional defiant disorder (ODD) are permitted to enroll in the study as long as ODD is not the primary focus of treatment.
  9. Subject has a first-degree relative (biological parent or sibling) with a history of schizophrenia, schizoaffective disorder, bipolar I disorder, or bipolar II disorder.
  10. Subject has generalized anxiety disorder or panic disorder that has been the primary focus of treatment at any time during the 12 months prior to screening or that has required pharmacotherapy any time during the 6 months prior to screening.
  11. Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood (eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders)
  12. Subjects with a history of persistent neurological symptoms attributable to serious head injury.
  13. History of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is exclusionary.
  14. Subjects taking anticonvulsants for seizure control currently or within the past 2 years are not eligible for study participation.
  15. Subject has uncontrolled thyroid disorder as evidenced by thyroid stimulating hormone (TSH) ≤ 0.8 x the lower limit of normal (LLN) or ≥ 1.25 x the upper limit of normal (ULN) for the reference laboratory
  16. Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) for any lifetime history on the C-SSRS Children's Lifetime/Recent assessment at screening.
  17. Subject has any history of attempted suicide or clinically significant suicidal ideation, in the opinion of the investigator.
  18. Subject has a history of severe allergies to more than 1 class of medication or multiple adverse drug reactions or has a history of allergic reaction or has a known or suspected sensitivity to any substance that is contained in the study drug formulations
  19. Subject has history of intolerance (safety) or lack of efficacy to stimulants.
  20. Subject has taken any antipsychotic medication within 6 months prior to screening.
  21. Subject has taken any herbal and/or complementary treatments, eg, St. John's Wort, within 6 months prior to Day 1.
  22. Subject has taken any antidepressant medication (eg, bupropion, selective serotonin reuptake inhibitor [SSRI]/ serotonin norepinephrine reuptake inhibitor [SNRI], tricyclic, etc) within 6 months prior to Day 1.
  23. Subject has ever taken any monoamine oxidase [MAO] inhibitor at any time.
  24. Subject is currently undergoing ongoing or newly initiated Cognitive Behavioral Therapy (CBT) for the treatment of ADHD; behavioral therapies, including school based interventions that were initiated less than one month prior to screening; or, behavioral therapy that in the opinion of the investigator would interfere with the subject's ability to participate for the duration of the study. School based interventions that have been in place for more than one month prior to screening will be allowed. Note: Unavoidable changes in school-based interventions that occur during study participation will not be exclusionary, but should be documented by the investigator, to the extent possible. Subjects should not be enrolled who, in the judgment of the investigator, are expected to start substantially different or more intensive course of behavioral therapy over the duration of their participation in the study.
  25. Subject or subject's family anticipates a move outside the geographic range of investigative site during the study period, or plans extended travel inconsistent with the recommended visit interval during study duration.
  26. Subject has history of, or current, malignancy other than non-melanomatous skin cancer.
  27. Subject has history of positive test for Hepatitis B surface antigen or Hepatitis C antibody.
  28. Subject is known to have tested positive for human immunodeficiency virus (HIV).
  29. Subject has participated in a classroom study within 6 months prior to the start of screening or has participated in any other clinical study with an investigational drug/product within 90 days prior to the start of screening or is currently participating in another clinical trial.
  30. Subject shows evidence of substance or alcohol use or is currently using tobacco or other nicotine-containing products, or has a positive urine drug screen (UDS) at screening. Note: Subjects with a positive UDS may be allowed to continue in the study, provided that the investigator determines that the positive test is as a result of taking medications as prescribed after consultation with the medical monitor.
  31. Subject is taking any disallowed medications for chronic treatment.
  32. Subject has previously been enrolled in a clinical trial of dasotraline (SEP-225289).
  33. Subject's parent/legal guardian is an investigational site staff member or the relative of an investigational site staff member.
  34. Subject is, in the opinion of the investigator, unsuitable in any other way to participate in this study.
  35. Subject's sibling or family member living in the same household is participating in the same laboratory classroom cohort for this study.
  36. Subject is unable to perform at the basic level of the standardized math test as defined in the laboratory classroom manual.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Years to 12 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03231800
Other Study ID Numbers  ICMJE SEP-360-311
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Sunovion
Study Sponsor  ICMJE Sunovion
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: CNS Mecdical Director Sunovion Pharmacetuicals Inc.
PRS Account Sunovion
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP